As of 2026, Wegovy (semaglutide) is a mature, mainstream option on the UK market for adults who need help to lose weight alongside diet, exercise, and behavioural support. It is a once-weekly injection used under qualified supervision, with doses increased in clear steps so tolerability can be monitored.
UK clinics and patients now have substantial real-world experience with prescribing, titration, and follow-up, alongside the original evidence from the STEP programme and ongoing use in practice. Supply and dose escalation are familiar parts of routine obesity care rather than an early “launch phase” story.
Wegovy remains one of the most effective licensed medical treatments for obesity when used as part of a broader plan. The table below sets out the standard month-by-month titration most new starters are guided through in practice, through to standard maintenance at 2.4 mg and, where appropriate, the higher 7.2 mg maintenance dose.
